Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tom's Of Maine Ingredients' Efficacy Weighed Against 'Natural' Claim In NAD Review

Executive Summary

Tom's of Maine's Naturally Dry Antiperspirant complies with FDA requirement that antiperspirants contain an aluminum salt-based active ingredient, but NAD says “naturally dry” misleads by implying that natural ingredients are responsible for product’s effectiveness. Brand owner Colgate also says an earlier class action settlement of "identical" ad claims precludes a NAD review.

You may also be interested in...



Oral Care, Topical Product 'Natural' Claims Paint Bullseye For Class Action

Class action complaints alleging misleading "natural" claims for food products have been stayed pending completion of FDA's look at whether it should formally define the term for use in food, but there is no parallel FDA consideration of how the term is used for oral care products and topicals.

Oral Care, Topical Product 'Natural' Claims Paint Bullseye For Class Action

Class action complaints alleging misleading "natural" claims for food products have been stayed pending completion of FDA's look at whether it should formally define the term for use in food, but there is no parallel FDA consideration of how the term is used for oral care products and topicals.

FTC Action On 'All Natural' Claims Likely To 'Embolden' Plaintiffs

Attorneys agree that FTC's announced settlements with personal-care companies for misleading "all-natural" claims likely will not be helpful to class-action defendants making primary-jurisdiction arguments and could actually spur more litigation, similar to trends following FDA warning letters.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel